Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05678959 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension Study of Ligelizumab in Food Allergy
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 163
- Enrollment target
NCT05678959 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 163 participants.
The verdict
NCT05678959, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 163 participants
- Enrollment target
Study Summary
This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.
Interventions
- DRUG Ligelizumab 120 mg
- DRUG Ligelizumab 240 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2023-04-27 |
| Est. Completion | 2025-03-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05678959
The ClinicalTrials.gov registry entry for NCT05678959 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ligelizumab 120 mg is the first listed.
NCT05678959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05678959 about?
NCT05678959 is a clinical study titled "Long-term Extension Study of Ligelizumab in Food Allergy". This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.
What is the current status of trial NCT05678959?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 163 participants. The study started on 2023-04-27. Estimated completion is 2025-03-06.
What interventions are being tested in trial NCT05678959?
The interventions under investigation include: Ligelizumab 120 mg (DRUG), Ligelizumab 240 mg (DRUG).
Who is sponsoring clinical trial NCT05678959?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.